Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HOXA9
REST API REST API
Homo sapiens
HOXA9 is differentially expressed in 120 experiments: 61 organism parts: kidney, liver, ... (59 more);, 127 disease states: normal, acute myeloid leukemia, ... (125 more);, 42 cell types 140 cell lines 12 compound treatments and 44 other conditions.
Synonyms HOX1, HOX1G
Orthologs hoxa9a (Danio rerio)   Hoxa9l (Rattus norvegicus)   Hoxa9 (Mus musculus)   F1NE14_CHICK (Gallus gallus)   hoxa9 (Xenopus laevis)   HOXA9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, proximal/distal pattern formation, sequence-specific DNA binding, multicellular organismal development, nucleus, transcription factor complex, definitive hemopoiesis, embryonic forelimb morphogenesis, mammary gland development, embryonic skeletal system development, sequence-specific DNA binding transcription factor activity, anterior/posterior pattern specification
InterPro Term Homeobox, Hox9_activation_N, Homeobox_Hox9, Homeobox_eu
UniProt Accession P31269, A8MVF3, E7EN04
Search EB-eye ENSG00000078399
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-MTAB-24, E-MEXP-433, E-MTAB-25, E-GEOD-1563, ... (14 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-MEXP-1437, E-GEOD-5258, E-GEOD-1880, E-MEXP-1006, ... (18 experiments)

Factor Value U/D Experiments
caki-1
1
E-MTAB-62
Bewo
1
E-MTAB-62
H1299
1
E-MTAB-62
SK-N-SH
1
E-MTAB-62
Breast cancer cell line
1
E-MTAB-62
GM07029
1
E-TABM-321
134 more value(s).


Cell type

studied in E-AFMX-5, E-MTAB-25, E-GEOD-5099, E-GEOD-3920, E-MEXP-669, ... (22 experiments)

Factor Value U/D Experiments
bronchial epithelial
2
E-MTAB-25, E-AFMX-5
stromal cell
2
E-GEOD-1460, E-MEXP-1327
CD34+
2
E-AFMX-5, E-TABM-145
fibroblast
1
2
E-GEOD-3920, E-MEXP-466, E-GEOD-3204
erythrocyte
1
E-MEXP-583
primary CD34- mesenchymal stem cell
1
E-MEXP-66
36 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-3860, E-MEXP-25, E-GEOD-2466, E-GEOD-1869, ... (29 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-MTAB-62, E-GEOD-1729
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
prostate cancer
2
E-MTAB-62, E-GEOD-6919
colorectal adenocarcinoma
1
2
E-AFMX-5, E-MTAB-62, E-TABM-145
nephrosclerosis
1
E-GEOD-20602
121 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-1417, E-GEOD-412, E-GEOD-2803, ... (10 experiments)

Factor Value U/D Experiments
glutamine
1
E-MEXP-941
camptothecin
1
E-GEOD-1417
control
18
1
E-GEOD-3284
5-aza-2'-deoxycytidine + trichostatin A
1
E-MEXP-1269
docosahexaenoic acid
1
E-MEXP-1014
none
3
3
E-GEOD-412, E-GEOD-5099, E-GEOD-1417, E-GEOD-995, E-GEOD-5824, ... (6 experiments)
6 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
1
E-GEOD-3494


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-125, E-GEOD-1725, E-GEOD-21340

Clinical info
studied in E-GEOD-2034

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-MTAB-62

Disease staging
studied in E-GEOD-1323, E-TABM-147

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Genotype
studied in E-MEXP-1437, E-GEOD-2466, E-GEOD-2292, E-TABM-321, E-GEOD-18005, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-GEOD-2466, E-GEOD-1926, E-TABM-26, E-TABM-15, E-GEOD-6919, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-980

Irradiate
studied in E-GEOD-1977

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Phenotype
studied in E-GEOD-1493, E-GEOD-1460

Protocol type
studied in E-GEOD-3254

RNAi
studied in E-GEOD-1676, E-MEXP-101

sampleID
studied in E-GEOD-24283

Sex
studied in E-GEOD-2466

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922

Test result
studied in E-GEOD-1926

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.554 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM